111.16
price up icon1.73%   1.89
pre-market  Vorhandelsmarkt:  111.22   0.06   +0.05%
loading
Schlusskurs vom Vortag:
$109.27
Offen:
$110
24-Stunden-Volumen:
6.04M
Relative Volume:
0.80
Marktkapitalisierung:
$138.43B
Einnahmen:
$28.75B
Nettoeinkommen (Verlust:
$480.00M
KGV:
300.43
EPS:
0.37
Netto-Cashflow:
$10.31B
1W Leistung:
+5.00%
1M Leistung:
-0.74%
6M Leistung:
+32.95%
1J Leistung:
+52.25%
1-Tages-Spanne:
Value
$109.73
$111.81
1-Wochen-Bereich:
Value
$104.92
$111.81
52-Wochen-Spanne:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,600
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
111.16 138.43B 28.75B 480.00M 10.31B 0.37
Drug Manufacturers - General icon
LLY
Lilly Eli Co
821.67 738.00B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
202.72 358.61B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
163.13 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
70.16 311.44B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.60 221.28B 64.17B 17.12B 18.10B 6.73

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
06:38 AM

Gilead to Expand R&D in China to Accelerate Access to Antiviral Treatments, Local GM Says - Yicai Global

06:38 AM
pulisher
Mar 27, 2025

Gilead Sciences CEO's pay climbed to $23.7 million - The Business Journals

Mar 27, 2025
pulisher
Mar 27, 2025

Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 MillionSEC Filing - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

What Analysts Are Saying About Gilead Sciences Stock - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

A Closer Look at Gilead Sciences's Options Market Dynamics - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com

Mar 27, 2025
pulisher
Mar 26, 2025

Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma

Mar 26, 2025
pulisher
Mar 26, 2025

Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's

Mar 26, 2025
pulisher
Mar 26, 2025

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Gilead price tries to regain footingForecast today26-03-2025 - Economies.com

Mar 26, 2025
pulisher
Mar 25, 2025

Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan

Mar 25, 2025
pulisher
Mar 25, 2025

Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law

Mar 25, 2025
pulisher
Mar 25, 2025

Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - ACCESS Newswire

Mar 25, 2025
pulisher
Mar 24, 2025

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader

Mar 24, 2025
pulisher
Mar 23, 2025

Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha

Mar 23, 2025
pulisher
Mar 22, 2025

Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 20, 2025

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN

Mar 20, 2025
pulisher
Mar 19, 2025

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead stock falls on report of HIV prevention cuts - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily

Mar 19, 2025
pulisher
Mar 19, 2025

Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research

Mar 19, 2025
pulisher
Mar 19, 2025

Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead slides as Trump administration puts HIV prevention funds under review - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets

Mar 19, 2025
pulisher
Mar 18, 2025

Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com

Mar 18, 2025

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$54.91
price up icon 0.75%
drug_manufacturers_general PFE
$25.01
price down icon 0.79%
$305.77
price up icon 0.02%
drug_manufacturers_general NVS
$111.40
price up icon 1.14%
drug_manufacturers_general MRK
$87.60
price down icon 0.58%
Kapitalisierung:     |  Volumen (24h):